Another Chinese biopharma lines up for a billion-dollar IPO

Damian Garde

drugmaker Simcere Pharmaceutical is plotting a Hong Kong IPO worth up to $ 1 billion, according to reports, joining a slew of local companies headed to the public markets.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS